Saladax Biomedical, Inc., an anchor tenant at Ben Franklin TechVentures®, announced the publication of a practice-changing study that shows the benefits of measuring and adjusting the amount of chemotherapy in a patient’s blood to minimize debilitating toxicity. Saladax has developed tests for Therapeutic Drug Monitoring (TDM), measuring and adjusting drug doses to reach a target. Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and often debilitating side effect of some chemotherapy and is often the reason why patients drop out of treatment. When patients received the right dose of paclitaxel, severe neuropathy was reduced by 78%. Read more: http://bit.ly/2fmGttE
Client & Alumni News
Study Shows That Therapeutic Drug Monitoring Can Reduce Chemotherapy Side Effects
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.